These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22417713)

  • 1. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
    Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
    Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
    Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
    Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
    Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.
    Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K
    BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.
    Lee KE; Chang BC; Kim HO; Yoon IK; Lee NR; Park HY; Gwak HS
    Ther Drug Monit; 2012 Jun; 34(3):275-82. PubMed ID: 22549502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
    McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
    Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
    Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA
    Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.
    Ichimura Y; Takahashi H; Lee MT; Shiomi M; Mihara K; Morita T; Chen YT; Echizen H
    Clin Pharmacokinet; 2012 Dec; 51(12):799-808. PubMed ID: 23018470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
    Zhang JE; Jorgensen AL; Alfirevic A; Williamson PR; Toh CH; Park BK; Pirmohamed M
    Pharmacogenet Genomics; 2009 Oct; 19(10):781-9. PubMed ID: 19741565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.